For more than two decades, the Applied Pharmaceutical Analysis (APA) Conference has served as a leading industry forum for advancing analytical science in drug discovery and development.
APA connects scientists across pharma, biotech, CROs, academia, and regulatory agencies to share technologies, case studies, and solutions that support the development of new therapies.

The Applied Pharmaceutical Analysis (APA) Conference, now in its 21st year, is a scientific forum dedicated to advancing analytical science in support of drug discovery and drug development. Organized by The Boston Society, a non-profit scientific organization, APA brings together scientists from pharmaceutical companies, biotechnology firms, CROs, academia, and regulatory agencies to exchange knowledge, discuss emerging technologies, and address real-world challenges in pharmaceutical analysis.

Hosted in Cambridge, Massachusetts—one of the world’s leading biotechnology hubs—APA provides a focused, industry-driven meeting organized by scientists for scientists. The conference promotes practical solutions, cross-disciplinary collaboration, and education for both experienced professionals and the next generation of pharmaceutical scientists.

21^st Applied Pharmaceutical Analysis (APA) Conference

September 14-15-16, 2026

Sanofi, Cambridge  

	Plenary Speaker Chongwoo Yu, PhD DCEP/OCP/OTS/CDER @ US Food and Drug Administration Regulatory Perspectives on Biomarker Bioanalysis			Plenary Speaker Dr. Lei Xie, PhD Prof. Pharmaceutical Sciences @ Northeastern University, Bouve College of Health Sciences Talk title TBA
	Heather Myler, PhD Senior Director, Head of Immunogenicity & New Modalities @ Takeda  The degree of validation needed for quantitative decision-making  biomarkers vs more exploartory biomarkers - title TBA			Ronald R. Bowsher, PhD, FAAPS Partner & CSO @ B2S Life Sciences Insights Into Immunogenicity Testing of Contemporary Peptide Therapeutics
	Jenny Valentine, PhD Senior Principal Scientist @ Regeneron A Streamlined Approach to Immunogenicity Assessment: From Analysis to Submission			Jason DelCarpini, PhD Director, Bioanalysis & Molecular Assays @ Moderna Real-world applications of AI in BA for small and large molecules - title TBA
	Sarah Bean, PhD Senior Director Laboratory Sciences @ Charles River Laboratories			Jeongsup Shim, PhD Senior Principal Scientist @ Genentech Simplifying PK and Biomarker Analysis: High-Sensitivity Single-Dilution Assays With The NULISA Platform
	Joshua Powers, PhD Senior Scientist @ BMS Emerging Hybrid LC-HRMS Assays for In Vivo DAR Shift Bioanalysis of ADCs			PJ Devine, PhD Scientific Director @ Bristol Myers Squibb Pharmaceutical Industry Perspectives On the Hype Vs Opportunities for New Approach Methodologies (NAMs) in Drug Discovery and Development
	Matthew Cerny, PhD Senior Principal Scientist @ Pfizer  Talk title TBA			Min Meng, PhD Chief Operations Officer, President of Resolian  Talk title TBA
	Amanda Hays, PhD Scientific Officer @ Bioagilytix qPCR & dPCR for GT bioanalysis in the non-clinical space - talk title TBA			Long Yuan, PhD Director, Head of Bioanalytical Group @ Biogen Quantitative Bioanalysis of Antibody-Oligonucleotide Conjugate
	Zachary Parsons, PhD Principal Scientist @ Bristol Myers Squib Talk title TBA			Michael McCoy, PhD Associate Director, In Silico ADME, DMPK & Modeling @ Takeda Mind the Gap: In Silicon ADME as a New Approach Methodology for Human Prediction
	Christine Bowman, PhD Principal Scientist @ Genentech Pralsetinib (tyrosin kinase inhibitor) - CYP3A4 anomaly - talk title TBA			Guangnong (Sunny) Zhang, PhD Director of Bioanalytical Chemistry @ Novo Nordisk  Translational & Clinical Development of Therapeutic siRNA ad ASOs: Current Industry Practices, Perspectives, and IQ Recommendations

APA 2026 Conference

The program will feature three focused workshops reflecting key areas of pharmaceutical analysis:

• Regulated Bioanalysis – addressing regulatory perspectives, emerging technologies, immunogenicity and ADA assessment, and the use of AI/ML in regulated bioanalysis and documentation.

• Discovery Bioanalysis & New Technologies – covering bioanalysis for oligonucleotides and antibody-conjugated oligos, complex and emerging modalities, biomarkers and multi-omics, and case studies on novel analytical platforms.

• Mechanistic ADME – exploring new methodologies for drug metabolism and toxicity assessment, metabolite analysis and alternative models, analytical strategies for new modalities, and approaches for dose and exposure prediction.

Together, these workshops bring leading scientists from across the pharmaceutical ecosystem to discuss current scientific challenges, share innovative technologies, and advance analytical approaches that support the development of new therapies.

2026 Regulated Bioanalysis Workshop 

Session I: Regulatory & Agency Perspectives

Session II: Emerging Technologies in Bioanalysis & Next Generation Modalities

Session III: Immunogenicity & ADA in Regulated Context

Session IV: AI/ML in Regulated Bioanalysis

2026 Discovery Bioanalysis and New Technologies Workshop 

Session I: Discovery BA for Oligonucleotide Therapeutics & Antibody-Conjugated Platforms

Session II: Discovery BA for Complex & Emerging Therapeutic Modalities

Session III: Biomarkers & Multi-Omics in Discovery

Session IV: Case Studies on Novel Technologies & Implementation

2026 Mechanistic ADME Workshop 

Session I: New Approach Methodology for Drug Metabolism & Toxicity

Session II: Mechanistic Insights Into Drug Metabolism, Human Metabolites, and Predictive Models

Session III: Mechanistic ADME of Emerging Therapeutic Modalities

Session IV: Mechanistic ADME for Dose and Exposure Prediction

DOWNLOAD 2025 APA PROGRAM GUIDE